or severe gestational and birth traumas (e.g., fetal hypIn addition, many patients have concomitant mood oxia or kernicterus), there are no immediate overt manisymptoms including depression and anxiety that may festations of schizophrenia. Rather, most individuals apcontribute to the 10% lifetime incidence of suicide in pear to function normally until they enter the greatest period of risk in late adolescence and early adulthood. schizophrenia.
as schizophrenia represents a constellation of diseases Prodromal symptoms and behaviors (i.e., those that herald the approaching onset of the illness) may include that share some phenotypic features. Differentiating among these possibilities will require the definitive idenattenuated positive symptoms (e.g., illusions, ideas of reference, magical thinking, superstitiousness), mood tification of specific causal factor(s).
symptoms (e.g., anxiety, dysphoria, irritability), cognitive symptoms (e.g., distractibility, concentration difficulCourse of Schizophrenia The time course of schizophrenia follows the fairly steties), social withdrawal, or obsessive behaviors to name a few (McGlashan, 1996; Yung and McGorry, 1996) . Bereotyped pattern depicted in Figure 1 . High-risk and longitudinal birth cohort studies have identified mild defcause many of these prodromal phenomena extensively overlap with the range of mental experiences and behavicits in social, motor, and cognitive functions during childhood and adolescence that may represent premoriors of persons in the ages of risk who do not subsequently develop schizophrenia, they cannot be considbid features of the illness (Jones, 1997). For example, subtle motor abnormalities during infancy (Walker and ered diagnostic. In the vast majority of cases, these prodromal manifestations, and subsequently positive Lewine, 1990 ) and deficits in social functioning, organizational ability, and intellectual functioning at ages and negative symptoms by which the diagnosis is made, develop gradually over a period of weeks, months or 16-17 have both been reported to be associated with the later appearance of schizophrenia (Davidson et al., even years beginning some time in the mid second through the third decade of life. Much remains to be learned about the etiology and Despite these limitations, the potential importance of pathophysiology of schizophrenia, but the efficacy of these findings is strengthened by the convergence of treatments for this disorder has been clearly demonother lines of evidence that support the hypothesis that strated (see Table 1 ). Although all available treatments schizophrenia is associated with abnormalities in thahave limitations in their effectiveness and are associated lamo-prefrontal connectivity (Figure 3) . For example, a with adverse side effects, it is an established fact that putative marker of MD axon terminals appear to be reantipsychotic medications can alleviate the psychotic duced in the PFC of subjects with schizophrenia (Lewis, symptoms of the disorder and prevent their recurrence 2000). In addition, basilar dendritic spines on PFC deep (Kane, 1996). Moreover, in doing so, antipsychotic drug layer 3 pyramidal neurons, a principal synaptic target treatment, strategically used, appears to reduce the deof the excitatory projections from the MD, have been gree of clinical deterioration that occurs from progresreported to be decreased by ‫%52ف‬ in subjects with sion of the illness. This has led to the hypothesis that schizophrenia (Garey et al., 1998; Glantz and Lewis, the early identification and treatment of schizophrenia 2000). In contrast, pyramidal neurons in at least some (before or soon after symptom onset) may reduce, or other cortical layers or regions of the same subjects, and even prevent, the cumulative morbidity of the illness in individuals with major depressive disorder, appear to (McGlashan, 1996) . Although pharmacotherapy prolack or to exhibit less marked changes in spine density.
vides the foundation for the treatment of schziophrenia, Since the elimination of presynaptic axon terminals typivarious psychosocial therapies can be useful adjuncts cally leads to resorption of the postsynaptic dendritic to drug treatment (Kane, 1996). spine, these observations are consistent with a reduced Until recently, most pharmacological treatments for number of afferents from the MD in schizophrenia. schizophrenia were based on synaptic modulation of In the primate visual system, monocular deprivation, dopamine neuronal systems mainly by antagonism of which leads to reduced cortical inputs from the thalapostsynaptic D 2 receptors. With the advent of the somus, has been associated with a decline in markers of called atypical antipsychotic drugs, this focus has now activity in cortical ␥-aminobutyric acid (GABA) neurons broadened to include other neurotransmitters such as (Hendry and Jones, 1988), including the expression of serotonin, norepinephrine, acetylcholine, histamine, and the mRNA for glutamic acid decarboxylase (GAD 67 ), the synthesizing enzyme for GABA. If these findings in the glutamate, as well as various neuropeptides and neu- systems level investigations and genetic approaches. niques), and comparison of the chromosomal locations of these genes with regions implicated in schizophrenia Current views hold that schizophrenia is probably a consequence of multiple interacting genes; individually, through linkage studies (Pulver, 2000) , may provide convergent approaches to the identification of specific vulthese genes may have relatively little independent influence, and they may not all be involved in every individual nerability genes. For example, a recent study of gene expression profiling in the dorsal PFC of subjects with who meets diagnostic criteria for the illness. Thus, assessment of the patterns of altered gene expression in schizophrenia revealed that, of over 250 gene groups, the group of genes encoding proteins involved in the the affected brain circuits of subjects with schizophrenia (using cDNA microarray technology or related techregulation of presynaptic function were most consis-sity on prefrontal cortical pyramidal neurons in schizophrenia. Arch.
